Oxurion nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of Diabetic Macular Edema (DME)

Leuven, Belgium, 20 September 2018 - Oxurion NV (Euronext Brussels: OXUR - formerly known as ThromboGenics), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diseases affecting the back of the eye, announced today the enrollment of the first patient in a Phase 1 open-label, multicenter, dose escalation study evaluating the safety of a single intravitreal injection of THR-687 for the treatment of patients with diabetic macula edema (DME).

THR-687 is a novel pan-RGD integrin antagonist currently being developed as a potential treatment for patients with diabetic eye disease. Preclinical studies have demonstrated THR-687's role in targeting multiple aspects of retinal vascular disease such as vessel leakage, inflammation, and neovascularization.

This Phase 1 study (THR-687-001 - NCT03666923) will primarily assess the safety of a single intravitreal injection of escalating dose levels of THR-687 in patients with DME. A maximum of 18 patients will be enrolled.

Patrik De Haes, MD, CEO of Oxurion nv, commented: "We are very excited about the progress we have made in advancing THR-687 (pan-RGD integrin antagonist) into the clinic. This is an important step in the clinical development of THR-687 and in establishing the safety profile of this pan integrin antagonist in patients with DME.  

This trial initiation follows the recent start of the Phase 1 clinical trial with THR-149 (PKal inhibitor), and the initiation of a Phase 2 with THR-317 (anti-PlGF) in combination with ranibizumab (Lucentis) in April, both for patients with DME. Our portfolio of comprehensive drug candidates addresses the clear unmet medical need for improved treatment options for this fast-growing diabetic eye disease market."

END
For further information please contact:

Oxurion NV Wouter Piepers, Global Head of Corp Coms & Investor relations Tel: [phone] [e-mail]
EU - Citigate Dewe Rogerson David Dible/ Sylvie Berrebi Tel: [phone] [e-mail]	US - LifeSci Public Relations Alison Chen Tel: [phone] [e-mail]

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. The company has built a diverse portfolio of disease-modifying therapies, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide.